We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Feature

5 Flash Points As FDA Gets Earful On Compounding Guidance

Law360 (May 25, 2018, 8:44 PM EDT) -- The U.S. Food and Drug Administration’s move to dramatically curtail large-scale compounding of lower-cost drugs is stoking fiery debate about benefits for patient safety and possible drug shortages. 

The debate played out in dozens of letters submitted by influential lobbying groups and various drug compounders. At issue is draft guidance the FDA floated in March to explain when big compounders known as “outsourcing facilities” can make products — ostensibly for patients with special medical needs — using bulk ingredients, as opposed to costlier FDA-approved products....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.